Singapore, Aug 17, 2010: China's Jiangbo Pharmaceuticals has announced that the company has received approval from the Shandong Food and Drug Administration ("Shandong FDA") to start the sales of Felodipine sustained release (SR) tablets.
After the Company received approval from the Chinese State Food and Drug Administration ("SFDA") to start producing Felodipine SR tablets in early June this year, Shandong FDA reviewed the company's manufacturing equipment and capacity to produce Felodipine SR tablets, examined the final products from its pilot production and approved the sale of Felodipine SR tablets. Felodipine SR is a well recognized generic drug to treat hypertension and is listed in China's Basic Medical Insurance Catalog for medical coverage.
As the current market leader recently increased the selling price of its Felodipine SR tablets, many of its distributors have turned to Jiangbo and expressed their interest in building a cooperative relationship. Jiangbo has engaged ten major distributors to sell this product in a number of different regions throughout China and believes that its strong distribution network will enable it to expand its market share in Felodipine SR tablets, quickly.
"We are very excited to begin the commercial launch of Felodipine SR tablets, which we believe will be a key revenue and profit growth driver for us in the next few years. We estimate revenue potential for this drug to be between $8 million and $12 million in the first twelve months of launch, with a projected gross margin of at least 70 percent," said Mr Linxian Jin, CEO of Jiangbo. "We believe the addition of Felodipine SR tablets will enrich our product portfolio and will strengthen our competitive market position, while providing more cost effective new medicine to meet growing patient demand."
| 
Comment on this article
